AB 004
Alternative Names: AB-004Latest Information Update: 17 Jan 2024
At a glance
- Originator AKSO Biopharmaceutical
- Class Antifibrotics; Hepatoprotectants; Recombinant fusion proteins
- Mechanism of Action B cell activating factor inhibitors; Interleukin 11 inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Idiopathic pulmonary fibrosis; Kidney disorders
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jan 2024 Discontinued for Non-alcoholic steatohepatitis in USA (Parenteral) (AKSO Biopharmaceutical pipeline, January 2024)
- 16 Jan 2024 Preclinical trials in Hepatic fibrosis in USA (Parenteral) prior to January 2024 (AKSO Biopharmaceutical pipeline, January 2024)
- 16 Jan 2024 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Parenteral) prior to January 2024 (AKSO Biopharmaceutical pipeline, January 2024)